AWH Capital’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

AWH Capital’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-65,000	Closed	-$1.98M	–	25
2022 Q2	$1.98M	Sell	65,000 -10,000	-13%	-$298K	2.66%	17
2022 Q1	$2.46M	Buy	+75,000	New	+$2.23M	2.53%	19
2020 Q4	–	Sell	-9,500	Closed	-$925K	–	51
2020 Q3	$925K	Buy	+9,500	New	+$1.19M	1.3%	25

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AWH Capital's RETA Position: Q3 2022 in Review

AWH Capital sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2022, closing a stake of 65,000 shares — an estimated $1.98M sold.

AWH Capital first reported a position in RETA in Q3 2020 and held it in 3 quarters. The position peaked at $2.46M in Q1 2022. 158 funds tracked by Wall St. Rank hold RETA as of Q3 2022.

AWH Capital reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2022 after selling out during the quarter.
AWH Capital sold 65,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2022, an estimated $1.98M.
AWH Capital first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2020 and held it in 3 quarters.
AWH Capital's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.46M in Q1 2022.
158 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2022.

Based on AWH Capital's 13F filing for Q3 2022, filed 14 Nov 2022.